Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Ariella who wrote (1395)	10/12/1998 11:35:00 PM
From: yosi s	Respond to of 1491

Ariella the article indeed is good. Next step is into phase 3 with a big pharma partner.

To: Ariella who wrote (1395)	10/13/1998 5:20:00 AM
From: Richard Huth	Read Replies (2) \| Respond to of 1491

This article is good for PARS, but I think it will not help the stock. It is more common spoken and not able to attract investors looking for biotech. The press coverage in the (to me) more important media is more mixed. NeuroInvestment is positive (but till now not a standard investment letter). BioCentury (read by a lot of investors) does not look that optimistic. PARS received coverage in the latest edition based on the trial results, but the basic sentiment was not very promising. Main statements: - till now all products failed in PhII/III, even after promising PhI/II-data. - no significance in different mortality. (- one has to be very careful in interpreting the mortality data. One dead less in placebo group, and the result would be reverse = more dead in treated group.) - there was no difference in the percent of patients with the highest neurological outcome scores after 6 months. - head trauma patients are a heterogeneous group, adding another layer of complexity to trials (to concentrate on the more severe cases might be promising, but one has to take whatever comes into hospital - first testing and than treating might not be possible everytime). Those are no news that will attract new investors (and these are the one we need, because we are all "in" already). Richard